

Martin Reck

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4950861/martin-reck-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

25,602
citations

26
h-index

38
g-index

38
ext. papers

34,768
ext. citations

18.3
avg, IF

6.48
L-index

#	Paper	IF	Citations
36	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015 , 373, 123-35	59.2	5539
35	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1823-1833	59.2	5381
34	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 2078-2092	59.2	2820
33	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018 , 378, 2093-2104	59.2	1704
32	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , 2018 , 378, 2288-2301	59.2	1695
31	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 2415-2426	59.2	1474
30	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>New England Journal of Medicine</i> , 2018 , 379, 2342-2350	59.2	1336
29	First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2220-2229	59.2	1236
28	Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2020-2031	59.2	960
27	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. <i>Journal of Clinical Oncology</i> , 2019 , 37, 537-546	2.2	637
26	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). <i>Journal of Clinical Oncology</i> , 2017 , 35, 3924-3933	2.2	495
25	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 387-401	35.1	398
24	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1505-1517	2.2	298
23	First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. <i>Journal of Clinical Oncology</i> , 2019 , 37, 992-1000	2.2	274
22	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 198-211	21.7	244
21	Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4012-9	2.2	197
20	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1600-1609	21.7	185

19	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 860-867	8.9	118
18	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50 . <i>Journal of Clinical Oncology</i> , 2021 , 39, 2339-2349	2.2	95
17	Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. <i>European Journal of Cancer</i> , 2019 , 116, 137-147	7.5	91
16	Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9501-9501	2.2	87
15	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021 , 39, 619-630	2.2	68
14	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 2067-2077	21.7	54
13	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score $\geq 50\%$: Randomized, Double-Blind Phase III KEYNOTE-598 Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2327-2338	2.2	53
12	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101308	2.2	42
11	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1349-1359	2.2	37
10	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	18
9	First-Line Immunotherapy for Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101497	2.2	17
8	Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2530-2542	2.2	14
7	PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS $\geq 50\%$: Data from KEYNOTE-024. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S8-S9	8.9	9
6	Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9521-9521	2.2	7
5	Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9016-9016	2.2	6
4	Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) \pm lenvatinib in patients (pts) with metastatic nonsquamous non-small-cell lung cancer (NSCLC): LEAP-006.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9118-TPS9118	2.2	5
3	Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?. <i>Drugs</i> , 2019 , 79, 1937-1945	12.1	4
2	ANTIangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.. <i>European Journal of Cancer</i> , 2022 , 166, 112-125	7.5	0

1 Systemtherapie für das kleinzellige Lungenkarzinom im Stadium IV. *Onkologe*, **2021**, 27, 876-886

0.1